Since going public in mid-2024, shares of healthcare and life science services company Tempus AI (NASDAQ: TEM) have gone on a wild rollercoaster ride. The firm’s initial public offering price was $37. The stock went on to eclipse $85 by February of 2025, only to fall to around $50 two months later. By October, shares rebounded above $100. Notably, around this time, MarketBeat cautioned investors, as Tempus flashed multiple overvaluation signals. The stock now trades near $54 per share, dropping almost 50% from its all-time high.
Tempus just reported its latest financial results, and unfortunately for the firm, it didn’t receive much love from the market, dropping 7% afterward. Still, with shares down so drastically, this is a company worth revisiting.
